ACR适用性标准®:宫颈浸润癌治疗前评估与随访2023年更新
该指南由美国放射学会多学科专家小组制定,基于GRADE等系统方法评估文献,采用RAND/UCLA适用性方法确定影像检查的适用性。内容涵盖宫颈浸润癌基于FIGO分类的治疗前分期、疗效评估及复发随访中影像的作用,强调准确判断肿瘤大小、局部侵犯及淋巴结和远处转移对治疗选择和预后判断的重要性。
要点
- 宫颈癌分期基于2018年修订的FIGO分类系统,该系统纳入了影像学和病理学数据。
- 影像在治疗前评估中起重要作用,包括初始分期和疗效评估。
- 准确判断肿瘤大小、局部侵犯、淋巴结及远处转移对治疗选择和预后判断很重要。
核心结论
- 影像在宫颈浸润癌治疗前评估(包括初始分期和疗效评估)中起重要作用。
- 准确判断肿瘤大小、局部侵犯及淋巴结和远处转移对治疗选择和预后判断很重要。
- 影像在局部和远处复发的检测与随访及后续治疗选择中起关键作用。
研究设计与样本
- 美国放射学会适用性标准是由多学科专家小组每年审阅的、针对特定临床情况的循证指南。
- 指南制定与修订过程支持对同行评议期刊医学文献进行系统分析。
- 采用GRADE等既定方法学原则评估证据。
- 采用RAND/UCLA适用性方法用户手册提供的方法学确定特定临床场景中影像和治疗程序的适用性。
- 在同行评议文献缺乏或模棱两可的情况下,专家可能是制定推荐意见的主要证据来源。
局限性
- 在同行评议文献缺乏或模棱两可的情况下,专家可能是制定推荐意见的主要证据来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Cervical cancer is a common gynecological malignancy worldwide. Cervical cancer is staged based on the International Federation of Gynecology and Obstetrics (FIGO) classification system, which was revised in 2018 to incorporate radiologic and pathologic data. Imaging plays an important role in pretreatment assessment including initial staging and treatment response assessment of cervical cancer. Accurate determination of tumor size, local extension, and nodal and distant metastases is important for treatment selection and for prognostication. Although local recurrence can be diagnosed by physical examination, imaging plays a critical role in detection and follow-up of local and distant recurrence and subsequent treatment selection. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
引用
- Shinagare AB, Burk KS, Kilcoyne A, et al. ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Invasive Cancer of the Cervix: 2023 Update. J Am Coll Radiol. 2024. PMID: 38823948. doi:10.1016/j.jacr.2024.02.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。